GC received a follow-up question on X:

"What's the biggest impediment [to a deal]? The sheer amount of debt? The number of creditors involved? What?"

GC's response:

"The amount, mostly. They would roll over for a decent deal at this point. Working through diligence on MANF but it is preclinical so always interest but they look later stage.

Cutanogen small market initially.

But we keep pushing. Something will hit."